Introduction
============

Transcutaneous electrical nerve stimulation (TENS) is a non-invasive treatment for chronic pain without significant side effects. Conventional TENS is delivered through surface electrodes to generate a strong, nonpainful sensation. The resulting stimulation of large diameter, deep tissue afferents produces pain relief by decreasing central sensitization and enhancing descending pain inhibition.[@b1-jpr-12-743] TENS has been used for the symptomatic treatment of chronic low back pain (CLBP) since the 1970s.[@b2-jpr-12-743] A recent meta-analysis concluded that TENS was superior to placebo or control in reducing pain intensity in non-specific low back pain; however, the selected studies exhibited heterogeneity.[@b3-jpr-12-743] Another recent meta-analysis found that TENS reduced CLBP for treatment periods \<5 weeks.[@b4-jpr-12-743] A number of other systematic reviews and meta-analyses concluded that TENS was ineffective for CLBP.[@b5-jpr-12-743]--[@b8-jpr-12-743] Several factors may contribute to negative outcomes in TENS clinical trials including inadequate stimulation dose,[@b3-jpr-12-743],[@b9-jpr-12-743],[@b10-jpr-12-743] use of effective co-interventions,[@b10-jpr-12-743] poor adherence,[@b10-jpr-12-743],[@b11-jpr-12-743] short study length,[@b10-jpr-12-743] and insufficient sample size.[@b10-jpr-12-743] Another issue may be the choice of outcome measures. In most TENS studies, pain intensity has been the primary outcome measure.[@b10-jpr-12-743] However, individuals with chronic pain use TENS in various ways to improve their quality of life.[@b12-jpr-12-743] It is possible that the focus on pain intensity has obscured overall TENS clinical utility. The uncertainty over the effectiveness of TENS in CLBP may be limiting its use despite an excellent safety profile and the need for non-pharmacological pain relief options.

More than half of individuals with CLBP suffer from impaired sleep.[@b13-jpr-12-743]--[@b15-jpr-12-743] The abnormalities include short sleep duration, delayed sleep onset, low sleep efficiency, increased awakenings, and altered sleep architecture.[@b13-jpr-12-743],[@b16-jpr-12-743]--[@b18-jpr-12-743] For these reasons, sleep is a relevant outcome measure of therapeutic effectiveness in CLBP. Moreover, chronic pain patients identify improved sleep as an important therapeutic goal.[@b19-jpr-12-743],[@b20-jpr-12-743] Several recent studies reported a decrease in self-reported pain interference with sleep following 2 months of TENS use in individuals with multi-site chronic pain.[@b21-jpr-12-743]--[@b23-jpr-12-743] Subjective and objective sleep measures may be discordant in CLBP, suggesting that perception of sleep and actual sleep may differ, and both should be evaluated.[@b16-jpr-12-743] The impact of TENS on objective sleep metrics in chronic pain has not been evaluated. The purpose of this real-world study was to evaluate the hypothesis that TENS users with CLBP will experience improvement in both self-reported and objective measures of sleep. Demonstration of an impact of TENS on both subjective and objective sleep in CLBP will increase confidence in its clinical value.

Methods
=======

Data source and study population
--------------------------------

The source for this retrospective cohort study was a database that collects real-world adherence and clinical data from individuals self-administering TENS for chronic pain. Data are uploaded to the database via a mobile application linked to the TENS device. The analyses were performed on a copy of the database with data collected between January 2, 2017 and August 29, 2018. The database includes self-reported user demographics, self-reported pain characteristics, pain ratings, objective adherence data, and objective sleep data.[@b22-jpr-12-743],[@b23-jpr-12-743] Submission of demographic and clinical data to the database via the mobile application is voluntary. In addition, capture of device data (ie, adherence and sleep) requires periodic synchronization of the device with the mobile application. For these reasons, although any individual contributing to the database was eligible for the study, only a subset provided a complete dataset necessary for inclusion.

Individuals meeting the following criteria were included as study participants: 1) age, gender, height, and weight recorded in database; 2) pain duration indicated as \>3 months, 3) pain frequency indicated as at least several times a week, 4) baseline pain rating recorded in database, 5) baseline pain interference with sleep ≥4 (ie, moderately disturbed sleep interference),[@b24-jpr-12-743] 6) list of pain sites included low back pain, 7) list of self-reported painful health conditions included prior back injury, 8) 10 weeks of continuous adherence data, starting on first day of device use, recorded in database, and 9) 10-week follow-up pain rating recorded in database. Prior back injury was a requirement to reduce the likelihood of including participants with incidental low back pain. In addition, tissue and nerve injury is associated with central sensitization[@b25-jpr-12-743] which may increase the likelihood of responding to TENS.[@b3-jpr-12-743]

All device users electronically consented to the use of their de-identified data for clinical research during the process of establishing a database account. This study was institutional review board exempt because the investigators used a database without personal identifying information (Code of Federal Regulations, Title 45, Department of Health and Human Services, Part 46, Protection of Human Subjects, Section 101(b)(4)). The reporting of this study followed the STROBE recommendations.[@b26-jpr-12-743]

Transcutaneous electrical nerve stimulation
-------------------------------------------

Contributors to the database used the same TENS device (Quell^®^, NeuroMetrix Inc., Waltham, MA, USA).[@b21-jpr-12-743],[@b22-jpr-12-743] Instructional materials were those normally included with commercial purchase; no additional training was provided. The user guide describes device placement, explains the importance of stimulation at a "strong but comfortable" level, and suggests daily use with at least 3 hours of stimulation. The device is placed on the upper calf and comprised a one-channel electrical stimulator, a stretchable band to secure the stimulator to the leg, and an electrode array.[@b21-jpr-12-743] The electrode array comprised four hydrogel pads, eacĥ15 cm^2^, configured as two 30 cm^2^ electrodes. When placed on the upper calf, the electrode array wraps around the leg overlapping sensory dermatomes S2 through L4. These dermatomes are typically targeted when treating low back pain with TENS,[@b27-jpr-12-743] although placement is often in the lower back region rather than distally. However, TENS has widespread effects that may obviate the need for co-localization of electrodes and pain.[@b23-jpr-12-743],[@b28-jpr-12-743]--[@b30-jpr-12-743] The peak output voltage and current are 100 V and 100 mA, respectively. The stimulation waveform is current regulated, rectangular and biphasic with a pulse duration of 280 µs. The inter-pulse intervals are pseudo-random with a mean frequency of 80 Hz. Prior to first use, the device is calibrated to the user's sensation threshold by an algorithm using both ascending and descending method of limits. Subsequent stimulation is automatically controlled. The initial therapeutic level is set so that the pulse charge is 5 dB above sensation. This level is typically perceived as "strong but comfortable". The stimulation intensity is then periodically increased by an adaptive algorithm to compensate for nerve de-sensitization and to activate deep tissue sensory afferents.[@b31-jpr-12-743] The user may also manually decrease or increase the intensity. Therapy sessions are 60 minutes, starting every other hour while the device is worn. Users also have the option of 30-minute sessions and 30-minute inter-session periods.

Several adherence parameters are electronically tracked by the TENS device. Utilization is the percentage of days with a minimum of 30 minutes of stimulation.[@b10-jpr-12-743] It is a measure of how regularly TENS is used. Prior studies have shown a dose--response association between utilization and chronic pain outcomes.[@b22-jpr-12-743],[@b23-jpr-12-743],[@b32-jpr-12-743] Sleep utilization is the percentage of nights with at least 30 minutes of stimulation during sleep. Hours/week is the average number of hours of stimulation per week. Sensation threshold is the current, in milliamps, at which electrical stimulation is first perceived. This value is determined by the aforementioned calibration algorithm. Stimulation intensity is the ratio of therapeutic current to the sensation threshold expressed in decibels.

Actigraphy
----------

Actigraphy is a non-invasive method to assess sleep in ambulatory settings.[@b33-jpr-12-743] Actigraphy devices are worn on the body and continuously record and analyze movements from which sleep metrics are derived under the principle that sleep is characterized by the relative absence of movement. The method has good sensitivity and moderate specificity for detecting sleep when compared to gold-standard polysomnography.[@b34-jpr-12-743]--[@b36-jpr-12-743] Traditional actigraphy cannot resolve sleep stages and therefore does not characterize sleep architecture. Common actigraphic sleep metrics include total sleep time (total time asleep from sleep onset to waking; measured in minutes), sleep efficiency (percentage of total time in bed trying to sleep that is actually spent sleeping; measured as %), sleep onset latency (time to fall asleep; measured in minutes), and wake after sleep onset (total time awake from sleep onset to waking; measured in minutes).[@b37-jpr-12-743] Consensus recommendations for sufficient sleep duration and acceptable sleep quality have been published by the National Sleep Foundation.[@b37-jpr-12-743],[@b38-jpr-12-743] Actigraphy can also identify periodic leg movements (PLMs), which are repetitive cramping or jerking of the legs during sleep,[@b39-jpr-12-743] with acceptable accuracy as referenced to polysomnography.[@b34-jpr-12-743],[@b40-jpr-12-743],[@b41-jpr-12-743] A PLM index ≥5/hour is considered abnormal.[@b39-jpr-12-743] Restless leg syndrome[@b39-jpr-12-743],[@b42-jpr-12-743] and chronic pain[@b43-jpr-12-743] are both associated with an elevated PLM index. Although PLMs are a marker for pathophysiological processes during sleep,[@b44-jpr-12-743]--[@b46-jpr-12-743] they may not directly disrupt sleep.[@b47-jpr-12-743],[@b48-jpr-12-743]

Most actigraphy devices are worn on the wrist; however, alternative locations such as the leg are valid.[@b33-jpr-12-743] The TENS device used in this study contains a 3-axis MEMS accelerometer for actigraphy measurements. Accelerometer signals are acquired at 50 Hz and processed to 1-minute epochs. Epochs are classified as sleep if the user is recumbent and the mean activity within the epoch is below a threshold. Following classification of epochs, sleep metrics are determined. For measurement of PLMs, the 50 Hz data stream is averaged down to 10 Hz and high pass filtered at 0.5 Hz. Individual leg movements and PLM sequences are automatically detected by applying World Association of Sleep Medicine standards.[@b49-jpr-12-743] Sleep data are stored on the device until the next connection with the mobile application. The actigraphic methods used in this study have been compared to polysomnography in patients referred to an academic sleep laboratory.[@b50-jpr-12-743],[@b51-jpr-12-743]

Actigraphic sleep measurements vary night to night and therefore sleep data should be aggregated over several nights to enhance reliability.[@b52-jpr-12-743] In this study, participant sleep was determined for an initial assessment (weeks 1--2) and a final assessment (weeks 9--10) as shown in [Figure 1](#f1-jpr-12-743){ref-type="fig"}. The representative sleep metrics for each assessment were the median value among all nights within the 2-week period with data, subject to a minimum of three nights.[@b52-jpr-12-743] Nights with total sleep time of \<4 hours or \>10 hours were excluded because of the likelihood of a data collection error, such as the device separating from the participant. Actigraphic sleep data were typically collected on nights during which participants used their TENS device therapeutically. Therefore, objective sleep outcomes may have reflected the concurrent benefit of TENS on sleep in addition to a cumulative effect. Evaluation of outcomes during TENS use is recommended for maximizing study fidelity.[@b10-jpr-12-743]

Pain ratings and participant stratification
-------------------------------------------

Pain ratings were electronically entered using the mobile application. Users who opted in to receiving push notifications on their smartphone received regular reminders to rate their pain. However, as a real-world study, the timing and frequency at which users rated their pain could not be controlled. Each pain rating included pain intensity and pain interference evaluated on an 11-point numerical rating scale (NRS) derived from the Brief Pain Inventory -- Short Form.[@b53-jpr-12-743] Four pain domains were tracked as follows: average pain intensity over the past 24 hours, pain interference with sleep over the past 24 hours, pain interference with activity over the past 24 hours, and pain interference with mood over the past 24 hours. Pain ratings defined over an NRS are ordinal variables; however, in this study they were analyzed as numerical variables.

[Figure 1](#f1-jpr-12-743){ref-type="fig"} shows the definition of the baseline and followup pain ratings. The baseline pain rating occurred on the first day (day 0) of TENS use or within the prior 6 days. The follow-up pain rating occurred between days 56 and 84 (ie, ±2 weeks of day 70). If more than one pain rating was available within the baseline or follow-up window, the rating closest to day 0 or day 70, respectively, was used. If more than one pain rating was available on a given day, the first was used. Study participants were stratified into the following two groups; those with improved pain interference with sleep (decrease ≥1 from baseline to follow-up[@b54-jpr-12-743]) and those with unimproved pain interference with sleep (no change or increase ≥1 from baseline to follow-up).

Statistical analyses
--------------------

Device usage, demographics, and pain characteristics were quantified by the mean and SD if numerical variables and by proportions if categorical variables. The statistical significance of group comparisons was evaluated by the two-sample *t*-test with equal variance for numerical variables. Key results were confirmed by the non-parametric two-sample Wilcoxon rank-sum test to verify that statistical significance was not a distribution artefact. The PLM index was log transformed prior to statistical testing to correct for a positive skew. Effect sizes were determined using the Cohen's *d* measure. The Pearson's chi-squared test was applied to categorical variables (eg, gender) and to contingency tables (eg, pain duration) to evaluate how likely the observed proportions arose by chance. A sensitivity analysis was conducted against changes to inclusion criteria and the definition of improved pain interference with sleep. Analyses were performed with Stata Version 15.1 (StataCorp, College Station, TX, USA).

Results
=======

A total of 554 TENS users met the inclusion criteria and formed the study group. This cohort was drawn from an initial population of 6,058 individuals who had a complete set of baseline data (criteria 1--4). A first set of 3,610 (59.6%) individuals were excluded because they did not indicate low back pain (criterion 5) or specify a prior back injury (criterion 6). An additional 649 (10.7%) individuals were excluded because of a baseline pain interference with sleep \<4 (criterion 7). Finally, 1,245 (20.6%) individuals were excluded because they either did not have 10 weeks of adherence data (criterion 8) or a follow-up pain rating (criterion 9) in the database.

There were 282 (50.9%, 95% CI: 46.7, 55.1) participants in the improved group and 272 (49.1%, 95% CI: 44.9, 53.3) in the unimproved group. The baseline to follow-up evaluation period was 67.0±5.0 days for the improved group and 67.8±5.8 days for the unimproved group (*P*=0.088). [Table 1](#t1-jpr-12-743){ref-type="table"} shows baseline demographics and pain characteristics for the two groups. The study participants were generally older adults, overweight, and equally split between male and female gender. Most participants reported chronic pain of ≥4 years duration that was characterized by every day pain. More than 95% of participants had moderate (32.3%, 4--6 points) or severe (64.3%, ≥7 points) pain at baseline. Participants reported substantial pain interference with sleep, activity, and mood at baseline. The only statistically significant difference between groups was for pain interference with sleep, which was higher in the improved group (7.4±1.9 vs 6.4±1.9, *P*\<0.001). Multi-site pain (≥3 sites) was reported by 92% of participants. The study participants had extensive pain-related medical histories, averaging over five painful health conditions. The three most commonly reported were arthritis (69.7%), herniated disc (50.4%), and prior neck injury (48.7%). The only statistically significant difference between the groups was for prior neck injury (improved 53.2% vs unimproved 44.1%, *P*=0.033).

[Table 2](#t2-jpr-12-743){ref-type="table"} shows the change in pain ratings from baseline to follow-up. The overall study population exhibited statistically significant improvement in all pain ratings. The improved group exhibited substantial reductions in pain interference and a moderate decrease in pain intensity. The unimproved group demonstrated worsening of pain intensity and pain interference with sleep and activity, but no change in pain interference with mood.

[Table 3](#t3-jpr-12-743){ref-type="table"} compares adherence in the two groups. The improved group had higher utilization (77.0±26.0 vs 70.2±29.2, *P*=0.004) and a trend toward higher sleep utilization (39.9±32.5 vs 35.1±31.0, *P*=0.081). There was no difference in weekly TENS use between the groups (42.0±23.8 hours/week vs 39.1±26.3 hours/week, *P*=0.176). There were no statistically significant differences between the two groups for either sensation threshold or stimulation intensity. The stimulation intensity was \~5 dB in both groups, which represents a 1.8-fold ratio between the therapeutic stimulation intensity and the sensation threshold.

[Table 4](#t4-jpr-12-743){ref-type="table"} compares actigraphic sleep metrics in the two groups. Sleep data were available for 58.9% of the improved group at the initial assessment and 41.8% at the final assessment. Similarly, sleep data were available for 58.8% of the unimproved group at the initial assessment and 39.0% at the final assessment. Sleep metrics were determined from an average of \~8 (range 3--14) nights of sleep for both groups at both assessments. At the initial assessment (weeks 1--2), there were no statistically significant differences between the groups. Participants in both groups had a mean total sleep time slightly below 7 hours (normal 7--9 hours) and a mean sleep efficiency at the low end of the normal range (normal \>85%). Both groups had an abnormal mean PLM index (normal \<5/hour). At the final assessment (weeks 9--10), there was a statistically significant difference in total sleep time between the groups, with the improved group sleeping 29 minutes longer than the unimproved group (424±81 vs 395±81, *P*=0.008 by two-group *t*-test and *P*=0.013 by two-sample Wilcoxon rank-sum test). In addition, the PLM index was lower in the improved group (6.8±8.8 vs 9.3±12.5, *P*=0.022 and *P*=0.035 by two-sample Wilcoxon rank-sum test). The effect sizes were 0.36 (95% CI: 0.09--0.62) for the total sleep time and 0.32 (95% CI: 0.05--0.59) for the PLM index.

Sensitivity analysis
--------------------

A sensitivity analysis was conducted to explore the impact of modifications to the inclusion criteria and definition of improved pain interference with sleep on the total sleep time and PLM index at the final assessment. The first sensitivity analysis eliminated the requirement for a minimum baseline pain interference with sleep of 4 (criterion 5). There was a decrease in the proportion of participants in the improved group (43.5%) but minimal impact on the difference in total sleep time between the groups (426±81 vs 399±79, *P*=0.005). The *P*-value for the group difference in the PLM index (6.8±9.0 vs 8.9±11.8, *P*=0.059) increased above the predetermined statistical significance level of 0.05. The second sensitivity analysis eliminated the requirement for 10 weeks of continuous adherence data (criterion 8). Neither the proportion of participants in the improved group (50.6%) nor the difference in total sleep time between the groups changed (425±81 vs 395±81, *P*=0.006). The *P*-value for the group difference in the PLM index (6.8±8.7 vs 9.1±12.4, *P*=0.034) remained under the predetermined statistical significance level of 0.05. The third sensitivity analysis redefined improved pain interference with sleep as at least a 2-point decrease. As expected, the proportion of participants in the improved group decreased (38.3%) but there was no change in the total sleep time difference between the groups (428±81 vs 399±82, *P*=0.010). Statistical significance for the group difference in the PLM index was lost (7.2±9.6 vs 8.5±11.5, *P*=0.134). Similar results were obtained for definitions of 15% and 30% relative decrease in pain interference with sleep. Overall, total sleep time appeared robust to modifications of the inclusion criteria and definition of improved pain interference with sleep while the PLM index exhibited sensitivity and should be interpreted with greater caution.

Discussion
==========

The purpose of this study was to determine if TENS users with CLBP who report a decrease in pain interference with sleep also exhibit improved actigraphic measures of sleep. There were two key findings. The first was that half of the study participants experienced at least a minimal clinically important change in pain interference with sleep over the 10-week evaluation period. These participants were classified as having improved pain interference with sleep. The improved and unimproved groups had similar demographics and baseline characteristics. Both groups had multi-site pain, moderate to severe pain at baseline, and multiple pain-related conditions. These features are consistent with poor health and multimorbidity associated with CLBP.[@b55-jpr-12-743] The only statistically significant difference at baseline was a higher pain interference with sleep in the improved group. A similar dependence on baseline pain interference with sleep was reported for pregabalin in neuropathic pain.[@b24-jpr-12-743]

The second key study finding was that the improved group exhibited better sleep by certain actigraphic sleep metrics compared to the unimproved group. Specifically, the improved group had longer total sleep time and a lower PLM index than the unimproved group at the end of the evaluation period (ie, weeks 9 and 10). The difference in total sleep time was not accompanied by differences in sleep efficiency, sleep onset latency, or wake after sleep onset. This pattern suggests that the two groups had similar sleep quality,[@b37-jpr-12-743] but participants in the improved group remained asleep longer. This is an important result as sleep duration predicts both near-term[@b56-jpr-12-743] and long-term[@b57-jpr-12-743] changes in chronic pain. The explanation for the selective impact on sleep duration is unclear but may relate to an influence of TENS on abnormal rest--activity patterns associated with chronic pain as discussed further below. The difference in PLM index between the two groups has a less direct interpretation. There is disagreement on whether PLMs directly disrupt sleep or are primarily markers for disturbed sleep.[@b47-jpr-12-743],[@b48-jpr-12-743],[@b58-jpr-12-743] In either case, the lower PLM index in the improved group is suggestive of decreased pathology during sleep.[@b58-jpr-12-743] Adherence variables for study participants were similar to successful long-term users of TENS.[@b59-jpr-12-743],[@b60-jpr-12-743] Therefore, the results in this study likely represent TENS effectiveness at high adherence.

Self-reported pain and sleep are sensitive to interpretation and influenced by psychological and social factors. An obvious limitation of self-reported sleep is the loss of consciousness during sleep, which makes individuals particularly poor reporters of sleep characteristics. Objective measures are generally insensitive to psychosocial factors and therefore should be more reliable across participants within a study and over time. Self-reports of low sleep duration and poor sleep quality are often not corroborated by actigraphy in chronic pain patients.[@b16-jpr-12-743],[@b18-jpr-12-743],[@b61-jpr-12-743] We believe this is the first study to demonstrate that TENS improves an objective outcome measure in a chronic pain cohort. This finding enhances confidence in a mechanistic link between TENS and improved clinical outcomes in patients with CLBP.

The present study suggests that TENS improves subjective and objective measures of sleep; however, the biological mechanisms are unknown. It is likely that a portion of the sleep benefit in the improved group causally followed from decreased pain.[@b62-jpr-12-743],[@b63-jpr-12-743] TENS activates descending pain inhibition and decreases sensitization of neurons in the ascending pain pathway.[@b1-jpr-12-743],[@b64-jpr-12-743] This modulation of pain processing may also explain the lower PLM index in the improved group. Although the neurologic generator for PLMs is unknown, evidence points to enhanced spinal cord excitability and a relationship to the spinal flexion reflex[@b65-jpr-12-743] which is closely associated with pain.[@b66-jpr-12-743],[@b67-jpr-12-743] It is possible TENS reduced both pain and PLMs through an overlapping enhancement of central inhibition and reduction in central excitation. Consistent with this hypothesis, several studies have demonstrated that TENS reduces the flexion reflex[@b68-jpr-12-743],[@b69-jpr-12-743] and spasticity.[@b70-jpr-12-743]--[@b72-jpr-12-743] There is also preliminary evidence that TENS reduces symptoms of restless leg syndrome;[@b73-jpr-12-743] however, that study did not measure PLMs.

It is also possible that TENS directly improved sleep through activation of CNS areas that regulate sleep rather than pain. There are reports of TENS altering sleep patterns in patients with CNS disease. For example, TENS may partially correct rest--activity rhythm abnormalities in patient with Alzheimer's disease.[@b74-jpr-12-743] The study authors hypothesized that TENS activates the hypothalamic suprachiasmatic nuclei, which regulates biological clocks. Abnormal rest--activity patterns have been reported in chronic pain conditions including fibromyalgia,[@b75-jpr-12-743] painful diabetic neuropathy,[@b76-jpr-12-743] and knee osteoarthritis with insomnia.[@b77-jpr-12-743]

A contribution from non-specific effects, including regression to the mean and placebo, cannot be excluded as this study was observational. Regression to the mean is unlikely to explain the group difference in total sleep time at the final assessment because both groups had similar sleep metrics at the first assessment. Objective outcomes may be less susceptible to placebo than patient reported outcomes;[@b78-jpr-12-743] however, physiological changes can occur in response to placebo.[@b79-jpr-12-743]

Study limitations
-----------------

This study had several limitations. First, the study was retrospective which may increase the potential for bias. It may be beneficial to confirm the findings with a prospective design. Second, the impact of co-interventions, such as pain medications, could not be evaluated because this information was not available in the data source. Concurrent analgesic use may have masked or enhanced the apparent therapeutic benefit of TENS. Third, patient reported assessment of sleep was limited to baseline to follow-up changes in pain interference with sleep. Although this is a recommended outcome measures in pain therapy trials,[@b80-jpr-12-743] other outcomes such as validated sleep instruments[@b81-jpr-12-743],[@b82-jpr-12-743] and a global sleep impression may have yielded different results. Fourth, actigraphic sleep data were available for a subset of participants. However, since the same proportion of participants in the two groups contributed, it is doubtful that group differences resulted from selection bias. Finally, the study results were obtained using a TENS device that utilized a specific electrode configuration and stimulation parameters, and therefore the conclusions may not generalize to other TENS instruments and methods.

Conclusion
==========

Regular TENS use improved subjective and objective sleep measures in individuals with CLBP. About half of the study participants exhibited improved (≥1 point) pain interference with sleep. When compared with the unimproved group, the improved group had longer total sleep time and fewer PLMs measured by actigraphy. These results suggest that one of the ways in which TENS may improve CLBP is through improvement in sleep. Future studies evaluating the clinical effectiveness of TENS in CLBP should consider sleep in addition to pain intensity.
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###### 

Comparison of demographics and baseline pain characteristics between study participants with improved and unimproved pain interference with sleep

  Characteristic                             Improved (282)   Unimproved (272)   *P*-value
  ------------------------------------------ ---------------- ------------------ -----------
                                                                                 
  Female gender: %                           55.3             50.7               0.280
  Age: mean (SD)                             55.2 (12.8)      54.4 (11.8)        0.443
  BMI (kg/m^2^): mean (SD)                   31.6 (7.7)       31.6 (7.2)         0.985
  Duration of pain (years): %                                                    0.064
   \<1                                       0.4              2.9                
   1--3                                      15.2             11.4               
   4--10                                     30.5             30.9               
   \>10                                      53.9             54.8               
  No. pain sites: mean (SD)                  5.9 (2.5)        6.0 (2.4)          0.593
  Lower extremity pain: %                    93.3             94.9               0.429
  Upper extremity pain: %                    71.6             71.3               0.936
  Neck pain: %                               61.0             61.0               0.993
  Head pain: %                               22.7             20.6               0.547
  No. painful health conditions: mean (SD)   5.7 (2.3)        5.8 (2.5)          0.458
  Pain frequency: %                                                              0.078
   Daily                                     96.1             98.5               
   Weekly                                    3.9              1.5                
  Time of worst pain: %                                                          0.194
   All day                                   62.4             67.3               
   At night or when sleeping                 8.5              6.6                
   In morning                                11.7             6.6                
   At rest                                   2.8              2.2                
   With activity                             10.3             12.9               
  Weather sensitive: %                       85.5             87.5               0.532
  Baseline pain: mean (SD)                                                       
   Pain intensity                            7.1 (1.7)        6.9 (1.9)          0.390
   Pain interference with sleep              7.4 (1.9)        6.4 (1.9)          0.000
   Pain interference with activity           7.7 (1.9)        7.5 (1.9)          0.236
   Pain interference with mood               7.3 (2.2)        7.3 (2.1)          0.922

**Notes:** No. pain sites, number of self-reported pain sites from feet/ankles, legs, hips, lower back, trunk, hands/wrist, arms, shoulders, neck, and head. No. painful health conditions, number of self-reported pain related conditions from arthritis, fibromyalgia, herniated disc, spinal stenosis, prior leg/foot injury, prior back injury, prior arm/hand injury, diabetes, complex regional pain syndrome, shingles, restless leg syndrome, multiple sclerosis, migraine, and cancer. Weather sensitive, % of participants responding "yes" to the question "Does weather affect your chronic pain?" *P*-value is for two-sample *t*-test with equal variance or Pearson's chi-squared test.

###### 

Change in pain ratings from baseline to follow-up in all study participants and for participants with improved and unimproved pain interference with sleep

  Pain rating: mean (SD)            All participants (N=554)                                Improved (N=282)                                        Unimproved (N=272)                                       *P*-value
  --------------------------------- ------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------- -----------
                                                                                                                                                                                                             
  Pain intensity                    −0.4 (2.4)[\*](#tfn3-jpr-12-743){ref-type="table-fn"}   −1.6 (2.3)[\*](#tfn3-jpr-12-743){ref-type="table-fn"}   0.9 (1.8)[\*](#tfn3-jpr-12-743){ref-type="table-fn"}     \<0.001
  Pain interference with sleep      −0.9 (2.8)[\*](#tfn3-jpr-12-743){ref-type="table-fn"}   −3.0 (2.0)[\*](#tfn3-jpr-12-743){ref-type="table-fn"}   1.4 (1.4)[\*](#tfn3-jpr-12-743){ref-type="table-fn"}     \<0.001
  Pain interference with activity   −1.1 (2.8)[\*](#tfn3-jpr-12-743){ref-type="table-fn"}   −2.5 (2.7)[\*](#tfn3-jpr-12-743){ref-type="table-fn"}   0.3 (2.0)[\*\*](#tfn4-jpr-12-743){ref-type="table-fn"}   \<0.001
  Pain interference with mood       −1.2 (2.8)[\*](#tfn3-jpr-12-743){ref-type="table-fn"}   −2.5 (2.7)[\*](#tfn3-jpr-12-743){ref-type="table-fn"}   0.3 (2.2)                                                \<0.001

**Notes:** *P*-value is for comparison of improved and unimproved groups by two-sample *t*-test with equal variance.

Indicates that group mean is greater or less than 0 by the one-sample *t*-test with *P*\<0.001.

Indicates that group mean is greater or less than 0 by the one-sample *t*-test with *P*\<0.05.

###### 

Comparison of TENS adherence over 10-week evaluation period between study participants with improved and unimproved pain interference with sleep

  Variable: mean (SD)          Improved (N=282)   Unimproved (N=272)   *P*-value
  ---------------------------- ------------------ -------------------- -----------
                                                                       
  Utilization (%)              77.0 (26.0)        70.2 (29.2)          0.004
  Sleep utilization (%)        39.9 (32.5)        35.1 (31.0)          0.081
  Hours/week                   42.0 (23.8)        39.1 (26.3)          0.176
  Sensation threshold (mA)     16.5 (13.5)        17.8 (14.3)          0.268
  Stimulation intensity (dB)   5.3 (5.3)          5.1 (5.6)            0.732

**Notes:** *P*-value is for two-sample *t*-test with equal variance. Sleep utilization, % of nights with at least 30 minutes of stimulation during sleep. Stimulation intensity, ratio of stimulation intensity to sensation threshold expressed in decibels. Utilization, % of days with at least 30 minutes of stimulation.

###### 

Comparison of actigraphic sleep metrics between study participants with improved and unimproved pain interference with sleep

                                 Weeks 1--2    Weeks 9--10                 
  ------------------------------ ------------- ------------- ------------- -------------------------------------------------------
                                                                           
  Total sleep time (min)         408 (74)      405 (80)      424 (81)      395 (81)[\*](#tfn6-jpr-12-743){ref-type="table-fn"}
  Sleep efficiency (%)           87.7 (0.7)    87.8 (0.7)    88.3 (0.8)    88.0 (0.7)
  Sleep onset latency (min)      30.3 (32.6)   28.0 (36.8)   32.4 (49.3)   25.1 (28.9)
  Wake after sleep onset (min)   27.2 (15.7)   28.6 (18.1)   26.9 (24.0)   28.2 (16.9)
  PLM index (PLM/hour)           8.0 (8.8)     8.7 (13.7)    6.8 (8.8)     9.3 (12.5)[\*](#tfn6-jpr-12-743){ref-type="table-fn"}
  Recording nights               8.8 (3.6)     8.6 (3.4)     8.8 (3.4)     8.3 (3.6)

**Notes:**

*P*\<0.05 by two-sample *t*-test with equal variance. PLM index log was transformed prior to statistical testing.

**Abbreviation:** PLM, periodic leg movement.
